Incannex Healthcare Limited
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $39.5M
- Price
- $3.15
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.85%
- Volume
- 52.5K
About
Incannex Healthcare Limited is an Australian company dedicated to the research, development, and commercialization of medicinal cannabinoid products. The firm offers pharmaceutical-grade cannabinoid compounds under its proprietary Incannex brand. Its product pipeline includes several key assets: IHL-42X: This compound is currently undergoing Phase II clinical evaluation for the treatment of obstructive sleep apnea (OSA). Incannex partners with The Alfred Hospital and Novotech on this specific clinical program. IHL-216A: Designed to address traumatic brain injury (TBI). Furthermore, the Monash Trauma Group, part of Monash University's Department of Neuroscience, is conducting a study on IHL-216A's protective effects against sports-related concussions. IHL-675A: A unique formulation combining hydroxychloroquine and cannabidiol, developed for both the prevention and management of a range of inflammatory conditions. These include acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), asthma, bronchitis, rheumatoid arthritis, and inflammatory bowel diseases. Originally established in 2001 as Impression Healthcare Limited, the company officially changed its name to Incannex Healthcare Limited in June 2020. Incannex maintains its corporate headquarters in Sydney, Australia.
Quick stats
Shares outstanding12.5M
Computed float11.4M
Float / shares90.9%
Cash runway (months)59.9
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001873875
Websitehttps://www.incannex.com
AI Summary
AI-generated1/18
minorneutralother
Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) FY26
Stonegate Capital Partners updated its coverage of Incannex Healthcare, describing IHL-42X as moving from preparation into active clinical execution with first-patient dosing underway in the DReAMzz study.
The trial is enrolling roughly 120 patients across nine dose combinations at 14 U.S. sites, with completion expected in mid-2027 and results intended to refine the Phase 3 design.
IXHL held $68.4M in unrestricted cash as of September 24, supporting at least 12 months of planned operations, though the 10-K notes substantial additional funding will be needed. The pipeline is increasingly concentrated on IHL-42X after IHL-675A's Australian RA Phase 2 was terminated for recruitment challenges.
Red flags
- IHL-675A Phase 2 RA study terminated due to recruitment challenges with insufficient data on efficacy or safety
- 10-K discloses substantial additional funding required beyond the 12-month runway
- research issued by a paid IR/advisory firm, not independent